Rion is a clinical-stage biotechnology company whose mission is to create clinically impactful and cost-effective therapies to address unmet medical needs.
Rion’s proprietary regenerative medicine platform is based on purified human exosomes. Called Purified Exosome Product (PEP), our platform is an innovative off-the-shelf biologic therapy that has the potential to address a wide array of clinical applications.
Regenerative medicine holds the promise of curing untreatable conditions to improve quality of life.
Rion is actively pursuing clinical programs in wound healing, cardiovascular disease, and women’s health. Our goal is to develop these therapies into effective and accessible medicines for any patient at their time of need, anywhere in the world.